Telomir Pharmaceuticals Reveals Promising Preclinical Diabetes Study

Telomir Pharmaceuticals, Inc., a leader in age-reversal science, announced promising preclinical results of its molecule, Telomir-1, for Type 2 diabetes. The study, using a zebrafish model, showed significant reductions in fasting plasma glucose and improved insulin sensitivity. Telomir-1 reversed insulin resistance to near pre-diabetic levels, enhanced oral glucose tolerance, and demonstrated improved survival rates in treated subjects.

This advancement could distinguish Telomir-1 from existing therapies by addressing the root causes of Type 2 diabetes rather than just symptoms. Telomir-1's mechanism involves normalizing iron metabolism to reduce oxidative stress and beta-cell damage, which are linked to insulin resistance.

Telomir's CEO, Erez Aminov, stated that these findings may transform diabetes management by targeting the root causes of insulin resistance as the company expands its research to other chronic diseases like Alzheimer's and osteoarthritis.